Model for estimating dopamine transporter occupancy and subsequent increases in synaptic dopamine using positron emission tomography and carbon-11-labeled cocaine

Biochemical Pharmacology

Volumn 53, Issue 1, 1997, Pages 43-52

  Gatley, S John ^a   Volkow, Nora D ^a   Gifford, Andrew N ^a   Ding, Yu Shin ^a   Logan, Jean ^a   Wang, Gene Jack ^a  

^a BROOKHAVEN NATIONAL LABORATORY   (United States)

Author keywords

cocaine; dopamine transport; drug abuse; methylphenidate; pharmacotherapy; positron emission tomography (PET)

Indexed keywords

1 [2 (BENZHYDRYLOXY)ETHYL] 4 (3 PHENYLALLYL)PIPERAZINE; 3BETA (4 FLUOROPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; 3BETA (4 IODOPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; CARBON 11; COCAINE; DOPAMINE; DOPAMINE TRANSPORTER; METHYLPHENIDATE; NOMIFENSINE; PSYCHOSTIMULANT AGENT;

ADDICTION; AMINE TRANSPORT; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BABOON; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE RELEASE; DOPAMINE UPTAKE; DRUG ABUSE; DRUG BINDING; DRUG BRAIN LEVEL; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MODEL; MOOD; MOUSE; NONHUMAN; NORMAL HUMAN; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; RAT; RECEPTOR OCCUPANCY; SYNAPSE; VOLUNTEER;

ANIMALS; CARBON RADIOISOTOPES; CARRIER PROTEINS; COCAINE; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; METHYLPHENIDATE; NERVE TISSUE PROTEINS; PAPIO; SUBSTANCE-RELATED DISORDERS; SYNAPSES; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0031060716     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(96)00655-7     Document Type: Article

References (71)

1. Fischman MW and Schuster CR, Cocaine self-administration in humans. Fedn Proc 41: 241-246, 1988.
2. Johanson CE and Fischman MW, The pharmacology of cocaine related to its abuse. Pharmacol Rev 41: 3-52, 1989.
3. Koob GF and Bloom FE, Cellular and molecular mechanisms of drug dependence. Science 242: 715-723, 1988.
4. Ritz MC, Cone EJ and Kuhar MJ, Cocaine inhibition of ligand binding at dopamine, norepinephrine and serotonin transporters: A structure-activity study. Life Sci 46: 635-645, 1990.
5. Sharkey J, Ritz MC, Schenden JA, Hanson RC and Kuhar MJ, Cocaine inhibits muscarinic cholinergic receptors in heart and brain. J Pharmacol Exp Ther 246: 1048-1052, 1988.
6. Sharkey J, Glen KA, Wolfe S and Kuhar MJ, Cocaine binding at σ receptors. Eur J Pharmacol 149: 171-174, 1988.
7. Gatley SJ, The activities of the enantiomers of cocaine, and some related compounds as substrates and inhibitors of plasma butyrylcholinesterase. Biochem Pharmacol 41: 1249-1254, 1991.
8. 3H]cocaine in striatum and its relationship to the dopamine transporter. Membr Biochem 7: 87-106, 1988.
9. Ritz MC, Lamb RJ, Goldberg SR and Kuhar MJ, Cocaine receptors on dopamine transporters are related to self administration of cocaine. Science 237: 1219-1223, 1987.
10. Hurd YL and Ungerstedt U, Cocaine: An in vivo microdialysis evaluation of its acute action on dopamine transmission in rat striatum. Synapse 3: 48-54, 1989.
11. Butcher SP, Liptrot J and Aburthnott GW, Characterization of methylphenidate and nomifensine induced dopamine release in rat striatum using in vivo brain microdialysis. Neurosci Lett 122: 245-248, 1991.
12. Guerin GF, Goeders NE, Dworkin SI and Smith JE, Intracranial self-administration of dopamine into the nucleus accumbens. Soc Neurosci Abstr 10: 1072, 1984.
13. Carlezon WA, Devine DP and Wise RA, Habit-forming actions of nomifensine in nucleus accumbens. Psychopharmacology (Berlin) 122: 194-197, 1995.
14. Giros B, Jaber M, Jones SR, Wightman RM and Caron MG, Hyperlocomotion and indifference to cocaine and amphet-amine in mice lacking the dopamine transporter. Nature 379: 606-612, 1996.
15. Fowler JS, Volkow ND, Wolf AP, Dewey SL, Schlyer DJ and MacGregor RR, Mapping cocaine binding sites in human and baboon brain in vivo. Synapse 4: 371-377, 1989.
16. Cook CE, Jeffcoat AT and Peres-Reyes M, Pharmacokinetic studies of cocaine and phencyclidine in man. In: Pharmacokinetics and Pharmacodynamics of Psychoactive Drugs (Eds. Barnett G and Chang NC), pp. 48-74. Biomedical Publications, Foster City, CA, 1985.
17. Volkow ND, Fowler JS, Logan J, Gatley SJ, Dewey SL, MacGregor RR, Schlyer DJ, Pappas N, King P, Wang GJ and Wolf AP, Carbon-11-cocaine binding compared at subpharmaco-logical and pharmacological doses: A PET study. J Nucl Med 36: 1289-1297, 1995.
18. 11C-methyl]-(-)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab 10: 740-747, 1990.
19. Volkow ND, Gatley SJ, Fowler JS, Logan J, Fischman M, Gifford AN, Pappas N, King P, Ding Y-S and Wang G-J, Cocaine doses equivalent to those abused by humans occupy most of the dopamine transporters. Synapse, in press.
20. Nicolaysen LC and Justice JB, Effects of cocaine on release and uptake of dopamine in vivo: Differentiation by mathematical modeling. Pharmacol Biochem Behav 31: 327-335, 1988.
21. Kawagoe KT, Garris PA, Wiedemann DJ and Wightman RM, Regulation of transient dopamine concentration gradients in the microenvironment surrounding nerve terminals in the rat striatum. Neuroscience 51: 55-64, 1992.
22. Garris PA and Wightman RM, Different kinetics govern dopaminergic transmission in the amygdala, prefrontal cortex, and striatum - An in vivo voltammetric study. J Neurosci 14: 442-450, 1994.
23. Grace AA, The tonic/phasic model of dopamine system regulation: Its relevance for understanding how stimulant abuse can alter basal ganglia function. Drug Alcohol Depend 37: 111-129, 1995.
24. Reith MEA, DeCosta B, Rice KC and Jacobson AE, Evidence for mutually exclusive binding of cocaine, BTCP, GBR 12935 and dopamine to the dopamine transporter. Eur J Pharmacol 227: 417-425, 1992.
25. Seeman P, Receptor Tables. Volume 2: Drug Dissociation Constants for Neuroreceptors and Transporters. SZ Research, Toronto, 1993.
26. McElvain JS and Schenk JO, A multisubstrate mechanism of striatal dopamine uptake and its inhibition by cocaine. Biochem Pharmacol 43: 2189-2199, 1992.
27. Uhl GR, Neurotransmitter transporters (plus): A promising new gene family. Trends Neurosci 15: 265-268, 1992.
28. 11C]cocaine binding to decreases in synaptic dopamine. Synapse 20: 137-144, 1995.
29. 11C]methylphenidate to the dopamine transporter in vivo: Insensitivity to synaptic dopamine. Eur J Pharmacol 281: 141-149, 1995.
30. Gifford AN, Gatley SJ and Ashby CR, Endogenously released dopamine inhibits the binding of dopaminergic PET and SPECT ligands in superfused rat striatal slices. Synapse 22: 232-238, 1996.
31. 3H]Cocaine binding sites in caudate-putamen. J Pharmacol Exp Ther 251: 131-141, 1989.
32. 3H]2β-carbomethoxy-3β-(4-fluorophenyl)tropane. Mol Pharmacol 36: 518-524, 1989.
33. 125I]iodophenyl)tropane-2β-carboxylate in vitro binding to dopamine and serotonin transporters under "physiological" conditions. J Neurochem 62: 978-986, 1994.
34. 125I]RTI-55 binding to cocaine-sensitive dopaminergic and serotonergic uptake sites in the human brain. J Neurochem 61: 1996-2006, 1993.
35. 3H]GBR 12935 binding to dopamine transporter is decreased in caudate nucleus in Parkinson's disease. J Neurochem 49: 617-621, 1987.
36. 3H cocaine binding associated with dopamine uptake sites in rat striatum and human putamen decrease after dopaminergic denervation and in Parkinson's disease. Naunyn Schmiedebergs Arch Pharamacol 329: 227-235, 1985.
37. 3H]GBR 12935 binding to dopamine uptake sites in the human brain. J Neurochem 53: 1400-1404, 1989.
38. Delforge J, Syrota A and Bendriem B, Concept of reaction volume in the in vivo ligand-receptor model. J Nucl Med 37: 118-125, 1996.
39. Xu C, Coffey LL and Reith MEA, Translocation of dopamine and binding of 2β-carbomethoxy-3β-(4-fluorophenyl) tropane (WIN-35,428) measured under identical conditions in rat striatal synaptosomal preparations. Inhibition by various blockers. Biochem Pharmacol 49: 339-350, 1995.
40. Krueger BK, Kinetics and block of dopamine uptake in synaptosomes from rat caudate nucleus. J Neurochem 55: 260-267, 1990.
41. Ross SB, Synaptic concentration of dopamine in the mouse striatum in relationship to the kinetic properties of the dopamine receptors and uptake mechanism. J Neurochem 56: 22-29, 1991.
42. Parsons LH and Justice JB, Quantitative approaches to in vivo brain microdialysis. Crit Rev Neurobiol 8: 189-220, 1994.
43. Gatley SJ, Volkow ND, Chen R, Fowler JS, Carroll FI and Kuhar MJ, Displacement of RTI-55 from the dopamine transporter by cocaine: Implications for pharmacotherapy of stimulant abuse and in vivo imaging studies. Eur J Pharmacol 296: 145-151, 1996.
44. Carroll FI, Lewin AH, Boja JW and Kuhar MJ, Cocaine receptor: Biochemical characterization and structure-activity relationships of cocaine analogues at the dopamine transporter. J Med Chem 35: 969-981, 1992.
45. Rothman RB, High affinity dopamine reuptake inhibitors as potential cocaine antagonists: A strategy for drug development. Life Sci 46: PL17-PL21, 1990.
46. Stine SM, Krystal JH, Kosten TR and Charney DS, Mazindol treatment for cocaine dependence. Drug Alcohol Dependence 39: 245-253, 1995.
47. Preston KL, Sullivan JT, Berger P and Bigelow GE, Effects of cocaine alone and in combination with mazindol in human cocaine abusers. J Pharmacol Exp Ther 258: 296-307, 1993.
48. Gawin FH, Riordan C and Kleber HD, Methylphenidate use in non-ADD cocaine abusers: A negative study. Am J Drug Alcohol Abuse 11: 193-197, 1985.
49. Margolin A, Kosten TR and Avants SK, A multicenter trial of bupropion for cocaine dependence in methadone-maintained patients. Drug Alcohol Depend 40: 125-131, 1995.
50. Alim TN, Rosse RB, Vocci FJ, Lindquist T and Deutsch SI, Diethylpropion pharmacotherapeutic adjuvant therapy for inpatient treatment of cocaine dependence - A test of the cocaine-agonist hypothesis. Clin Neuropharmocol 18: 183-195, 1995.
51. Gatley SJ, Pan D, Chen R, Charurvedi G and Ding Y-S, Affinities of methylphenidate derivatives for dopamine, norepinephrine and serotonin transporters. Life Sci 58: PL231-PL239, 1996.
52. 11C]d-threo-Methylphenidate: A new PET ligand for the dopamine transporter. I. Characterization of its binding in the baboon brain. J Nucl Med 36: 2298-2305, 1995.
53. 11C]d-threo-Methylphenidate: A new PET ligand for the dopamine transporter. II. Studies in the human brain. J Nucl Med 36: 2162-2168, 1995.
54. Volkow ND, Wang G-J, Fowler JS, Gatley SJ, Ding Y-S, Logan J, Hitzemann R and Liberman J, Relationship between psychostimulant induced "high" and dopamine transporter occupancy. Proc Natl Acad Sci USA, 93: 10388-10392, 1996.
55. Volkow ND, Ding Y-S, Fowler JS, Wang G-J, Logan J, Gatley SJ, Dewey S, Ashby C, Liebermann J, Hitzeman R and Wolf AP, Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in human brain. Arch Gen Psychiatry 52: 456-463, 1995.
56. Wang GJ, Volkow ND, Hitzemann RJ, Wong C, Angrist B, Burr G, Pascani K, Pappas N, Lu A, Cooper T and Lieberman JA, Behavioral and cardiovascular effects of intravenous methylphenidate in normal subjects and cocaine abusers. Eur Addict Res, in press.
57. Cline EJ, Scheffel U, Boja JW, Carroll FI, Katz JL and Kuhar MJ, Behavioral effects of novel cocaine analogs: A comparison with in vivo receptor binding potency. J Pharmacol Exp Ther 258: 1174-1179, 1992.
58. Vaugeois JM, Bonnet JJ, DuterteBoucher D and Costentin J, In vivo occupancy of the striatal dopamine uptake complex by various inhibitors does not predict their effects on locomotion. Eur J Pharmacol 230: 195-201, 1993.
59. Rothman RB, Grieg N, Kim A, De Costa BR, Rice KC, Carroll F and Pert A, Cocaine and GBR 12909 produce equivalent motoric responses at different occupancy of the dopamine transporter. Pharmacol Biochem Behav 43: 1135-1142, 1992.
60. 11C]β-CIT binding to monoamine transporters in the monkey and human brain. Synapse 16: 93-103, 1994.
61. 123I]β-CIT SPECT measures of dopamine transporter availability in human cocaine addicts. Psychopharmacology 122: 358-362, 1995.
62. Volkow ND, Gatley SJ, Fowler JS, Logan J, Dewey SL, Ding Y-S, Chen R, Pappas N, King P, MacGregor RR, Kuhar MJ, Carroll FI and Wolf AP, Long-lasting inhibition of in vivo cocaine binding to dopamine transporters by 3β-(4-iodophenyl)tropane-2-carboxylic acid methyl ester; RTI-55 or βCIT. Synapse 19: 206-211, 1995.
63. Milner HE, Beliveau R and Jarvis SM, The in situ size of the dopamine transporter is a tetramer as estimated by radiation inactivation. Biochim Biophys Acta 1190: 185-187, 1994.
64. 2 antagonist pimozide inhibits up-regulation of dopamine release and uptake induced by repeated cocaine. J Neurochem 60: 376-379, 1993.
65. Meiergerd SM and Schenk JO, Striatal transporter for dopamine: Catechol structure-activity studies and susceptibility to chemical modification. J Neurochem 62: 998-1008, 1994.
66. Eshleman A, Dunigan C, Shamoo A and Eldefrawi M, ATP enhances catecholamine uptake into PC12 cells. Life Sci 56: 1613-1621, 1995.
67. Chiodo LA, Dopamine-containing neurons in the mammalian central nervous system: Electrophysiology and pharmacology. Neurosci Biobehav Rev 12: 49-90, 1988.
68. Einhorn LC, Johansen PA and White FJ, Electrophysiological effects of cocaine in the mesoaccumbens dopamine system: Studies in the ventral tegmental area. J Neurosci 88: 100-111, 1988.
69. Pitts DK and Marwah J, Cocaine and central monoaminergic neurotransmission: A review of electrophysiological studies and comparison to amphetamine and antidepressants. Life Sci 42: 949-968, 1988.
70. 2 receptors regulating the release of dopamine and acetylcholine in the nucleus accumbens and striatum. Pharmacol Biochem Behav 41: 841-846, 1992.
71. Dackis CA and Gold MS, New concepts in cocaine addiction: The dopamine depletion hypothesis. Neurosci Behav Rev 9: 469-477, 1985.